

Fluorescent Imaging Agent

Caution: For Laboratory Use. A product for research purposes only.

Annexin-Vivo™ 750

Product Number: NEV11053

DESCRIPTION: *Annexin-Vivo™ 750* is a targeted fluorescence imaging agent comprising a selective protein, Annexin A5 and a near-infrared (NIR) fluorochrome. This agent has been developed to enable *in vivo* visualization and quantification of the membrane-bound phospholipid, phosphatidylserine, exposed in the outer leaflet of the cell membrane lipid bilayer during the early stages of apoptosis.

MATERIAL (*Ready to use: No dilution required*)

CONTENTS: Each vial contains 10 mouse doses of *Annexin-Vivo 750* in solution. *Annexin-Vivo 750* is supplied in 1000 µL of 25 mM HEPES/NaOH, 140 mM NaCl, pH 7.4. The packaged material provides sufficient reagent for imaging approximately 10 mice (weighing ~25 grams each) when using the recommended dose of 100 µL of *Annexin-Vivo 750* per mouse.

PROPERTIES: The physical characteristics of *Annexin-Vivo 750* can be found in **Table 1** and **Figure 1**.

STORAGE & HANDLING:

- Upon receipt, *Annexin-Vivo 750* should be **IMMEDIATELY STORED AT 2-8 °C AND PROTECTED FROM LIGHT**.
- When stored and handled properly, *Annexin-Vivo 750* is stable for up to six months.
- Before opening the vial check to ensure that the solution is present at the bottom of the vial.

Table 1. Annexin-Vivo 750 Characteristics

Property	Specification
MW	35,000 g mol ⁻¹
Fluorescence ¹	
• Excitation	755 nm
• Emission	772 nm
Absorbance	748 nm
Purity ²	>95 %
Appearance	Blue solution

1. Absorbance and fluorescence maxima of *Annexin-Vivo 750* in water
 2. As determined by RP-HPLC and measuring absorbance at 750 nm.




Figure 1. Absorbance and fluorescence emission spectra of *Annexin-Vivo 750* in 1x PBS.

IN VIVO IMAGING AND APPLICATIONS:

- The generally recommended procedure for *in vivo* imaging with *Annexin-Vivo 750* is administration via intravenous injection and imaging **2 hours post injection**.
- ***Annexin-Vivo 750* will clear from tissues after ~3 days after which repeat injection and imaging may be performed for longitudinal studies. However it is recommended that a pre-injection baseline image be taken prior to reinjection and imaging.**
- *Annexin-Vivo 750* enables imaging of therapeutic response in oncology models, and has applications in cardiovascular disease, transplant rejection, and pancreatitis models.

NOTES:

- *PerkinElmer's Annexin-Vivo 750* is intended for research purposes only and is not for human use. It must be used by or directly under the supervision of a technically qualified individual experienced in handling potentially hazardous materials. Please read the Material Safety Data Sheet (MSDS) provided for this product.
- Several of *PerkinElmer's* products and product applications are covered by U.S and foreign patents and patents pending. Our products are not available for resale or other commercial uses without a specific agreement from *PerkinElmer*.

PerkinElmer, Inc.
549 Albany Street
Boston, MA 02118 USA
P: (800) 762-4000 or (+1) 203-925-4602
www.perkinelmer.com/nenradiochemicals

For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs

Copyright ©2010, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners.

